Login to Your Account



Handicapping the COPD Race

LAMA/LABA Do, but Later: Forest Reports Delay in Filing

By Randy Osborne
Staff Writer

Thursday, August 15, 2013
us_resized.jpg

The falter by Forest Laboratories Inc. and Spanish partner Almirall SA in submitting a new drug application (NDA), originally planned for the first quarter of this year, pushes the duo back somewhat in the race by pharma and biotech firms to win approval of the magic potion, long-acting muscarinic antagonist (LAMA) with a long-acting beta agonist (LABA) for chronic obstructive pulmonary disease (COPD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription